

Impact of the draft European Data Protection Regulation and proposed amendments from the rapporteur of the LIBE committee on scientific research

SUMMARY

We welcome the provisions in the European Commission's proposal for a Data Protection Regulation (2012/0011(COD)) to support research that is vital to improve the lives, health and wealth of people in the European Union. The Commission's proposal strikes an appropriate balance between protecting the rights and interests of individuals and facilitating scientific research for public good.

We are very concerned that amendments proposed by the rapporteur of the LIBE committee will prevent or severely impair scientific research studies using personal data.

To ensure that the Regulation does not inhibit ground-breaking medical and social research:

- it is essential that Article 83 and the associated derogations that facilitate research are maintained as the Regulation moves through the legislative process;
- amendments are needed to clarify the research provisions to ensure these achieve their intended purpose; and
- amendments are needed to clarify the scope of the Regulation and ensure that the use of pseudonymised data in scientific research is regulated proportionately.



Why the use of personal data is important to scientific research¹

Individuals' patient records provide a vital resource for health research. These records provide the basis for observational studies of the factors underpinning health and disease. Observational studies have led to breakthroughs such as understanding the association between smoking and lung cancer, and the association between high blood pressure and cardiovascular disease.

Access to patient records also helps researchers identify suitable participants to invite to take part in studies, such as clinical trials that test how well new treatments or diagnostic screening programmes work. Increasingly, these trials also include genetic analysis of participants, for example to study the factors that determine how an individual responds to a specific treatment, for example herceptin treatment in breast cancer. Genetic data are also used in population studies to understand more about the causes of common diseases.

Some research in the social sciences also depends on a similar model of access to personal data and the statistics derived from personal data, for example studying whether government policies have been effective and how they could be improved. Increasingly researchers are seeking to link together administrative information about one individual across a range of sectors – for example health, education and welfare – to build a better picture how these complex interactions affect our lives and wellbeing.

Using personal data in scientific research therefore has the potential to generate important benefits by improving our understanding of society, health and disease. By supporting patient recruitment, the use of personal data also has an important role to play in creating a facilitative environment in the EU for public, charitable and commercial collaboration on clinical trials and other studies that will also promote economic growth.

To capitalise on these benefits, it is vital that the EU strikes an appropriate balance between facilitating the safe and secure use of personal data for scientific research and the rights and interests of individuals.

How is the use of personal data in scientific research governed?

Generally scientific researchers use anonymised data wherever possible. However, sometimes it is necessary to access information that can directly or indirectly identify a specific individual (see box 1). Scientific research with personal data takes place within a robust ethical framework and research ethics committees play an important role in ensuring that an individual's personal data are used in research in a way that is proportionate to the potential benefits for society as a whole.

In the EU, the use of personal data is tightly controlled within a complex regulatory and governance framework. The European Data Protection Directive, transposed into Member State laws, is a key aspect of this. The regulation and governance of the use of personal data is also closely related to other relevant legislation, such as the European Clinical Trials Directive. The complexity of the current regulatory and governance framework causes difficulties and delays for scientific research studies seeking legitimate access to personal data.ⁱ

Data Protection Regulation: potential impacts on scientific research

Article 83 and associated research derogations

The draft Data Protection Regulation appears to provide a number of derogations – or exceptions – from particular requirements for the use of 'personal data' for historical, statistical and scientific research purposes. In order to qualify for these derogations, personal data must be processed in accordance with conditions set out in Article 83: personal data should not be used if anonymous data

¹ Scientific research may include research in medicine and the natural and social sciences. This statement does not consider the implications of the Regulation for studies in law, politics and contemporary history that rely on alternative data sources to those discussed in this statement.

would be sufficient and, if possible, any identifying information should be kept separately from other information. The derogations do not exempt scientific research studies from all the requirements set out in the Regulation. However, the derogations do, for example, enable the processing of personal data without consent and for personal data to be held for extended periods for scientific research purposes. We warmly welcome this approach since it provides a framework that balances the facilitation of research and its associated benefits, with the protection of the interests of research participants (see case study box A).

The rapporteur of the LIBE committee (LIBE rapporteur) has proposed amendments to Articles 81 and 83 that would severely restrict the use of personal data for scientific research purposes without consent. Article 7 of the Regulation requires consent to be “specific, informed and explicit”, which is often difficult to achieve in scientific research. For example health research often relies on a ‘broad consent’ model where participants consent for their data to be used for a variety of research studies under certain conditions. In other situations specific consent may introduce bias in the results, increasing the chance of researchers reaching the wrong answer, with potentially dangerous consequences. The combination of the LIBE rapporteur’s amendments and the requirements for consent is therefore highly problematic for scientific research. Vital research from across Europe that produces benefits for public health and healthcare would not be possible if the LIBE rapporteur’s amendments were to pass.

We call on the EU institutions and Member States to prioritise the protection of Article 83 and ensure that the associated derogations for scientific research are maintained as the Regulation moves through the legislative process.

There are a number of issues around Article 83 and the associated derogations that would benefit from clarification. The lack of clarity in the current Data Protection legislation has contributed to a risk-averse culture among those sharing and using data for scientific research. Misinterpretation of the current regulatory and governance framework has led to delays to, and even halted, research that would otherwise be in the public interest (see case study box B). To avoid replicating these difficulties, it is essential that any lack of clarity is minimised in the new Regulation. We call on the EU institutions and Member States to seek clarification of Article 83 and associated issues for scientific research, including:

- clarifying that the reference to Article 83 within Article 81 is intended to link the two sections, rather than to impose an additional restriction on research;
- clarifying that Recital 40 and Article 6.4 about processing of personal data for other purposes intends scientific research to be viewed as a not incompatible purpose in itself; and
- ensuring that requirements on the right of the data subject to information (Article 14) and data storage (Article 5) do not impose disproportionate burdens on research.

We call on the EU institutions and Member States to seek clarification of Article 83 and the associated derogations to ensure that these provide the intended support for scientific research.

Scope of the Regulation

It is important that the research community is clear about how ‘personal data’ relates to the different types of data used in research (see box 1), since the scope determines which research studies are brought within the remit of the Regulation and therefore must comply with its requirements.

The Regulation is not explicit on whether pseudonymised data are intended to be included within its scope. Pseudonymised or key-coded data underpin a substantial amount of scientific research, for example large-scale population-based research involving hundreds of thousands of participants, such as biobanks and patient and population cohorts (see case study box C). Therefore the inclusion of pseudonymised data within the scope will dramatically increase the regulatory burden on research. If pseudonymised data are intended to be included in the scope, we suggest that amendments will be needed to protect the status of well-established use of pseudonymised data in scientific research and to ensure that the regulatory burden is proportionate to risk. This should reflect the fact that although re-identification from pseudonymised data may be technically possible, stringent operational and contractual conditions have been established in health research to minimise the opportunity of re-identification.

The LIBE rapporteur's amendments would clearly bring pseudonymised data within the scope of the Regulation. However, these amendments would create a system in which the use of pseudonymised data is subject to most of the same regulatory requirements as identifiable data. This would create a disproportionate regulatory burden for the use of pseudonymised data in scientific research.

Clarification is also needed around 'genetic data' and 'data concerning health' to ensure that these definitions are only intended to apply to personal data that falls within these categories, rather than all related data or tissue samples.

We call on the EU institutions and Member States to seek clarification of the scope of the Regulation and to ensure that the use of pseudonymised data in scientific research is handled proportionately by the Regulation.

BACKGROUND

Public support for the use of patient data in health research

Public opinion appears broadly in favour of patient records being used for health research. In 2009 a survey of 1,179 UK adults found that 74 per cent were willing to allow access to their personal medical records for medical research.ⁱⁱ Evidence also suggests that patients want to know about opportunities to take part in research and access to their patient records is necessary to facilitate this. Of 1.2 million UK women contacted to take part in the UK Collaborative Trial of Ovarian Cancer Screening, only 32 complained they had been contacted.ⁱⁱⁱ A poll of nearly 1,000 adults in 2011 found that 72 per cent of respondents would like to be offered chances to take part in research trials^{iv} and a study of around 600 UK families with rare diseases across the UK showed that only 24 per cent felt they are given enough information about clinical trials.^v

Box 1: different forms of data used in scientific research

Identifiable data – these include information such as names, addresses and dates of birth. There are also aspects of data that could become identifiable when combined with other data or when they relate to a rare event, such as diagnosis with a rare illness. Identifiable data are needed when future contact is needed with the participant, for example to contact them to take part in a study.

Key-coded or pseudonymised data – these cannot directly identify an individual, but are provided with an identifier that enables the data subject's identity to be re-connected to the data by reference to a separate database containing the identifiers. Pseudonymised data can be used to link information across different data sets. These data can often, but not always, be used in place of identifiable data.

Anonymised data – these data cannot be connected to the original data subject. Anonymised data are suitable when no contact is needed with the participant or where the data do not need to be linked to any other data sources. Generally researchers use anonymised data wherever possible.

Case study box A: Example of where it is not practical or possible to obtain consent for the use of patient data in research

Power lines and the risk of childhood leukaemia

Cancer registries were used to identify 33,000 children with cancer, aged up to 14 years. The study showed that, compared with children who lived greater than 600 metres from a power line at birth, those who lived within 200 metres had an increased risk of leukaemia (relative risk: 1.69). This study involved information that a child of a particular age lived in a specific postcode. These two pieces of information alone could enable the identification of an individual child. However, it would not have been feasible – or proportionate – to seek individual consent from all 33,000 children.

Identifying and contacting participants for research studies

Researchers sometimes need to process personal data to identify eligible people to take part in a study and invite them to participate and it would not be possible to seek their specific consent for this. For example:

- The Heart Protection Study was the largest trial in the world of cholesterol-lowering therapy and antioxidant vitamin supplements in people at increased risk of heart disease. Over 20,000 people have been recruited to this study, which required access to contact details for people with specific medical conditions.
- UK Biobank is a health resource with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses including cancers and heart disease. 500,000 men and women aged 40-69 have agreed to take part. Without access to individuals' names and addresses prior to their consent to take part, it would not have been possible for the research team to invite them to participate.
- The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was designed to investigate the efficiency of different screening techniques for ovarian cancer. Invitations to participate in UKCTOCs were sent to routine patients in participating trial centres. 1.2 million women were initially contacted by post and over 200,000 eligible women agreed to take part in the study.

This shows the importance of protecting Article 83 and the associated derogations for research.

Case study box B: Example of delays caused by lack of clarity in existing governance structure

Breast Cancer Campaign Tissue Bank

The Breast Cancer Campaign Tissue Bank brought together four local tissue bank sites to create the UK's first national breast cancer tissue bank after a wide scale review by Campaign showed that the main barrier to progress in breast cancer research in the UK was a shortage of good quality tissue. The Tissue Bank's central database contains pseudonymous patient data stored outside of the UK National Health Service (NHS) and also links to datasets within the NHS, to enable researchers to access relevant data on the samples. It therefore has to comply with the Data Protection Act.

Breast Cancer Campaign had to spend significant time and money liaising with legal advisors, NHS trusts and the researchers who run the Tissue Bank, to ensure that the wording of patient information sheets and consent forms complied with the Data Protection Act. Although researchers generally have a good understanding of relevant legislation for tissue banking, including the Human Tissue Act, they are often confused and less confident about the implications of the Data Protection Act and need extensive support to implement this appropriately. This highlights the importance of clarity in the data protection legislation to ensure that scientists without the necessary support around data protection – unlike those working with the Tissue Bank – do not simply abandon vital research activities.

Swine flu study

In autumn 2009, studies into pandemic 'flu were fast-tracked due to the need for rapid research into the disease. This involved co-ordinating research in 314 NHS organisations across 640 research study sites, and ensuring fast set-up times. In a UK National Institute of Health Research-funded study conducted across several sites, questionnaires were sent out to eligible patients identified through anonymous datasets. At most sites the research team was permitted to print out address labels and post the questionnaires. However, local interpretation of the Data Protection Act and other legal requirements at one site, prevented the research team from accessing patients' names and addresses and therefore a member of the clinical care team was required to take on this role. Although a member of the clinical care team agreed to undertake this activity, their other priorities meant that only 30 out of 200 questionnaires were ever sent out at that site.

These examples show the importance of having a clear regulatory and governance framework for the use of patient data in research and highlight the need to seek clarification of the relevant parts of the Regulation.

Case study box C: Example of the importance of pseudonymised data in research

Collaborative Oncological Gene-environment Study

The Collaborative Oncological Gene-environment Study is a European Commission funded project involving 140 groups worldwide and a total of 200,000 individual participants. The project is analysing the genetic variation associated with developing breast, ovarian and prostate cancer and combining this with information on environmental and lifestyle factors. The project combines genotyping, statistical modelling and examination of ethical, legal and social issues to develop a comprehensive understanding of how knowledge of genetic factors can enable better tailoring of interventions to individuals in the prevention and treatment of these cancers. Individual participants' data will be pseudonymised so that it can be shared securely between researchers. An overly restrictive approach to pseudonymisation has the potential to compromise the genetic analysis of samples and use of data by the research groups because of the strict regulatory requirements this would impose. Foreseeably, this may delay the translation of these findings into more effective interventions for individuals.

The UK National Genetics Reference Laboratories (NGRL)

NGRL have developed and curate a database of genetic variants identified by clinical diagnostic laboratories. The purpose of the database is to aid the interpretation of new or rare genetic variants by sharing genetic data and information on what these genetic data mean for patients. NGRL also facilitates research and investigations into these new or rare variants. NGRL relies on databases where the information is pseudonymised rather than anonymised. Pseudonymised data are important to resources of this type because they enable greater quality control and increase the value of data sets compared to anonymised records, for example:

- When anonymised data are entered into a database it is impossible to identify and correct errors or to amend it when new information becomes available. Pseudonymised data allow the original data submitter to remain in control of their data and to make changes or withdraw the data if necessary.
- Internationally, there is an increasing movement towards aggregation of data: this creates larger, more valuable data sets and helps users find all data on variants of interest quickly. Because of the network-like development of links between databases, the same piece of data can be aggregated from more than one source. When this occurs, pseudonymisation means the data sets can be edited to prevent the same piece of data appearing more than once, which could skew the data set. This would not be possible with anonymised data.
- Pseudonymisation allows researchers and diagnostic laboratories to link the information to other data sources that they have legitimate access to. This linkage means that information can be combined to enrich the data, but this is not possible where data has been completely anonymised.

These examples show value of pseudonymisation in research and the importance of ensuring that pseudonymised data are handled proportionately by the Regulation.

CONTACT DETAILS

We would be happy to provide further information or a representative to discuss this response further. Please contact Dr. Beth Thompson, Policy Adviser, Wellcome Trust at: b.thompson@wellcome.ac.uk or +44 (0) 20 7611 7303.

ⁱ Academy of Medical Sciences (2011) *A new pathway for the regulation and governance of health research* <http://www.acmedsci.ac.uk/p99puid209.html>

ⁱⁱ Wellcome Trust (2009) *Monitor I* <http://www.wellcome.ac.uk/About-us/Publications/Reports/Public-engagement/WTX058859.htm>

ⁱⁱⁱ Menon U. et al. (2008) *Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study* <http://www.ncbi.nlm.nih.gov/pubmed/19008269>

^{iv} AMRC/Ipsos MORI (2011) *Public support for research in the NHS* <http://www.ipsos-mori.com/researchpublications/researcharchive/2811/Public-support-for-research-in-the-NHS.aspx>

^v Rare Disease UK (2010) *Experiences of Rare Diseases: An Insight from Patients and Families* <http://www.raredisease.org.uk/experiences-of-rare-diseases.htm>